IPO Plans: Sai Life Sciences filed draft papers with SEBI, the Indian securities regulator, to raise funds through an Initial Public Offering (IPO).
IPO Structure: The IPO will consist of two parts:
Fresh Issue: The company will issue new equity shares worth Rs 800 crore.
Offer for Sale (OFS): Existing shareholders, including promoters and investors like TPG Capital, will sell some of their shares.
Company Profile:
- Full-Service CRO-CDMO: Sai Life Sciences operates as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), providing a comprehensive service for drug development.
- Global Reach: They work with pharmaceutical and biotechnology companies worldwide, indicating a strong market presence.
- Large Workforce: With over 3,000 employees across R&D and manufacturing sites in India, UK, and the USA, Sai Life Sciences appears to have a well-established infrastructure.
